These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 15961978)

  • 1. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
    Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine markedly raises the plasma concentrations of repaglinide.
    Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
    Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2008 Dec; 66(6):818-25. PubMed ID: 18823304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
    Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
    J Clin Pharmacol; 2008 Mar; 48(3):311-21. PubMed ID: 18187595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
    He J; Qiu Z; Li N; Yu Y; Lu Y; Han D; Li T; Zhao D; Sun W; Fang F; Zheng J; Fan H; Chen X
    Eur J Clin Pharmacol; 2011 Jul; 67(7):701-7. PubMed ID: 21327909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.
    Xiang Q; Cui YM; Zhao X; Yan L; Zhou Y
    Pharmacology; 2012; 89(1-2):105-10. PubMed ID: 22398664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
    Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
    Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
    Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
    Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
    Kalliokoski A; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
    Kalliokoski A; Backman JT; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2008 Nov; 18(11):937-42. PubMed ID: 18854776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
    Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
    Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLCO1B1 polymorphism and oral antidiabetic drugs.
    Kalliokoski A; Neuvonen PJ; Niemi M
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
    Hedman M; Antikainen M; Holmberg C; Neuvonen M; Eichelbaum M; Kivistö KT; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2006 Jun; 61(6):706-15. PubMed ID: 16722833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
    Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC
    Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.
    Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2008 Jan; 65(1):78-86. PubMed ID: 17635496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
    Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis.
    Zhou S; Xiang Q; Mu G; Ma L; Chen S; Xie Q; Zhang Z; Cui Y
    Curr Drug Metab; 2019; 20(4):266-274. PubMed ID: 30636597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
    Bidstrup TB; Damkier P; Olsen AK; Ekblom M; Karlsson A; Brøsen K
    Br J Clin Pharmacol; 2006 Jan; 61(1):49-57. PubMed ID: 16390351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
    Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
    Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.